Bemarituzumab

5 trials 1 recruiting Orphan designation

Filter these 5 trials by condition, phase, country and more.

Open in Search →

5 Registered trials

1 Recruiting

4 Completed trials

3 Sponsors

22 Countries

Phase III

Phase II

Phase I/II

Phase III: 2 Phase II: 2 Phase I/II: 1

Oversight events:

4 serious breaches 1 temporary halt across 3 trials

View oversight register →

Indications tested

Gastric cancer 2 Adenocarcinoma gastric 1 Squamous cell carcinoma of head and neck 1 Endometrial adenocarcinoma 1 Breast cancer 1

Sponsors using this IMP

Amgen Inc. 3 Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH 1 Institut De Cancerologie De L Ouest 1

All trials

5 total

Bemarituzumab in patients with FGFR2b-positive advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed… Recruiting

2024-512484-31-00 Phase II 2 countries Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH
Bemarituzumab plus Chemotherapy and Nivolumab versus Chemotherapy and Nivolumab Alone (FORTITUDE-102) Ended

2023-505458-16-00 Phase III 12 countries Amgen Inc.
A Study Evaluating Bemarituzumab in Solid Tumors with FGFR2b Overexpression Ended

2023-505455-44-00 Phase I/II 15 countries Amgen Inc.
Study Comparing Bemarituzumab plus Chemotherapy with Placebo and Chemotherapy in Previously Untreated Advanced Gastric or Gastroesophageal J… Ended

2023-505457-40-00 Phase III 18 countries Amgen Inc.
Open-label non-randomized multicentric phase 2 study evaluating the combination of bemarituzumab + FLOT chemotherapy in perioperative settin… Ended

2024-514078-29-00 Phase II 1 country Institut De Cancerologie De L Ouest

Showing 1–5 of 5 trials

← All drugs A–Z